Rigel Pharmaceuticals Inc logo

RIGL

Rigel Pharmaceuticals Inc

$0.83

Earnings Summary

Revenue
$22.41Mn
Net Profits
$-19.04Mn
Net Profit Margins
-84.95%

Highlights

Revenue:

Rigel Pharmaceuticals Inc’s revenue jumped 4.02% since last year same period to $22.41Mn in the Q3 2022. On a quarterly growth basis, Rigel Pharmaceuticals Inc has generated -24.85% fall in its revenue since last 3-months.

Net Profits:

Rigel Pharmaceuticals Inc’s net profit jumped 9.14% since last year same period to $-19.04Mn in the Q3 2022. On a quarterly growth basis, Rigel Pharmaceuticals Inc has generated -41.1% fall in its net profits since last 3-months.

Net Profit Margins:

Rigel Pharmaceuticals Inc’s net profit margin jumped 12.66% since last year same period to -84.95% in the Q3 2022. On a quarterly growth basis, Rigel Pharmaceuticals Inc has generated -87.75% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Rigel Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.13
EPS Estimate Current Year
-0.13

Highlights

EPS Estimate Current Quarter:

Rigel Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.13 - a 7.47% jump from last quarter’s estimates.

EPS Estimate Current Year:

Rigel Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.13.

Key Ratios

Key ratios of the Rigel Pharmaceuticals Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.08
Return on Assets (ROA)
-0.33
Return on Equity (ROE)
-5.54

Highlights

Earning Per Share (EPS):

Rigel Pharmaceuticals Inc’s earning per share (EPS) jumped 0% since last year same period to -0.08 in the Q2 2022. This indicates that the Rigel Pharmaceuticals Inc has generated 0% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Rigel Pharmaceuticals Inc’s return on assets (ROA) stands at -0.33.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Rigel Pharmaceuticals Inc’s return on equity (ROE) stands at -5.54.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2015-11-03
-0.17
-0.08
52.94%
2016-03-08
-0.14
-0.14
0%

Company Information

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.

Organisation
Rigel Pharmaceuticals Inc
Headquarters
1180 Veterans Boulevard, South San Francisco, CA, United States, 94080
Employees
165
Industry
Health Technology
CEO
Raul Rodriguez

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*